UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant 🗵

Filed by a Party other than the Registrant \Box

Check the appropriate box:

- Preliminary Proxy Statement
- \Box Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2



DIAMEDICA THERAPEUTICS INC.

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):

- ☑ No fee required
- □ Fee paid previously with preliminary materials
- □ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



DIAMEDICA THERAPEUTICS INC 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS, MIN 55305

Your Vote Counts!

DIAMEDICA THERAPEUTICS INC.

2025 Annual General Meeting Vote by May 14, 2025 11:59 PM ET




V61958-P24853

You invested in DIAMEDICA THERAPEUTICS INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 15, 2025.

Get informed before you vote

View the Notice and Proxy Statement and 2024 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 1, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



*Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voti	Voting Items	
1.	To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified (Voting Proposal One).	
	Nominees:	
1a.	Michael Giuffre, M.D.	For
1b.	Richard Kuntz, M.D., M.Sc.	For
1c.	Tanya Lewis	S For
1d.	Daniel O'Connor	For
1e.	James Parsons	For
1f.	Rick Pauls	For
1g.	Charles Semba, M.D.	For
2.	To consider a proposal to appoint Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 and to authorize the Board of Directors to fix our independent registered public accounting firms remuneration (Voting Proposal Two).	Sec. 10
3.	To approve, on an advisory (non-binding) basis, our executive compensation (Voting Proposal Three).	For

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".